MDM2 and breast carcinoma: The result showed that ZLM-7 treatment could alter the expression of 14-3-3 sigma and MDM2 by upregulating the expression of 14-3-3 sigma, and interestingly, downregulating MDM2 expression in breast cancer cells (Figure 1C,D).